Benefits and adverse events among elderly patients receiving concurrent chemoradiotherapy for locally advanced non-small cell lung cancer: Analysis of the Okayama lung cancer study group trial 0007

Nagio Takigawa, Katsuyuki Kiura, Yoshihiko Segawa, Katsuyuki Hotta, Akihiko Tamaoki, Yoshiyuki Tokuda, Takuya Nagata, Kazuhiko Watanabe, Kenichi Gemba, Tomonori Moritaka, Naokatsu Horita, Hiromasa Takeda, Niro Okimoto, Mitsuhiro Takemoto, Keitaro Matsuo, Tetsu Shinkai, Masahiro Tabata, Hiroshi Ueoka, Susumu Kanazawa, Mitsune Tanimoto

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Introduction: Thoracic radiotherapy (RT) with concurrent chemotherapy may be offered to selected elderly patients with locally advanced non-small cell lung cancer. The Okayama Lung Cancer Study Group (OLCSG) 0007 trial with patients up to 75 years showed that with concurrent RT, docetaxel and cisplatin (DP) chemotherapy was an alternative to mitomycin C, vindesine, and cisplatin (MVP) chemotherapy. Methods: Of the 99 patients in the DP arm, 73 were younger than 70 years and 26 were 70 years or older. Of the 101 patients in the MVP arm, 75 were younger than 70 years and 26 were 70 years or older. Overall survival (OS) and progression-free survival (PFS) were calculated using the Kaplan-Meier method and were compared using an early period weighted log-rank test. Toxicities and treatment intensities were compared by χ and t tests, respectively. Results: OS and PFS tended to be longer in the DP arm versus MVP arm: median OS (months), 27.5 versus 22.9 (p = 0.109) and 25.6 versus 23.4 (p = 0.064) in the ≥70-year and

Original languageEnglish
Pages (from-to)1087-1091
Number of pages5
JournalJournal of Thoracic Oncology
Volume6
Issue number6
DOIs
Publication statusPublished - Jun 2011

Fingerprint

Chemoradiotherapy
Non-Small Cell Lung Carcinoma
Lung Neoplasms
docetaxel
Drug Therapy
Cisplatin
Disease-Free Survival
Survival
Radiotherapy
Vindesine
Mitomycin
Thorax
Therapeutics

Keywords

  • Chemotherapy
  • Elderly
  • Non-small cell lung cancer
  • Radiation

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Benefits and adverse events among elderly patients receiving concurrent chemoradiotherapy for locally advanced non-small cell lung cancer : Analysis of the Okayama lung cancer study group trial 0007. / Takigawa, Nagio; Kiura, Katsuyuki; Segawa, Yoshihiko; Hotta, Katsuyuki; Tamaoki, Akihiko; Tokuda, Yoshiyuki; Nagata, Takuya; Watanabe, Kazuhiko; Gemba, Kenichi; Moritaka, Tomonori; Horita, Naokatsu; Takeda, Hiromasa; Okimoto, Niro; Takemoto, Mitsuhiro; Matsuo, Keitaro; Shinkai, Tetsu; Tabata, Masahiro; Ueoka, Hiroshi; Kanazawa, Susumu; Tanimoto, Mitsune.

In: Journal of Thoracic Oncology, Vol. 6, No. 6, 06.2011, p. 1087-1091.

Research output: Contribution to journalArticle

Takigawa, N, Kiura, K, Segawa, Y, Hotta, K, Tamaoki, A, Tokuda, Y, Nagata, T, Watanabe, K, Gemba, K, Moritaka, T, Horita, N, Takeda, H, Okimoto, N, Takemoto, M, Matsuo, K, Shinkai, T, Tabata, M, Ueoka, H, Kanazawa, S & Tanimoto, M 2011, 'Benefits and adverse events among elderly patients receiving concurrent chemoradiotherapy for locally advanced non-small cell lung cancer: Analysis of the Okayama lung cancer study group trial 0007', Journal of Thoracic Oncology, vol. 6, no. 6, pp. 1087-1091. https://doi.org/10.1097/JTO.0b013e318213f86a
Takigawa, Nagio ; Kiura, Katsuyuki ; Segawa, Yoshihiko ; Hotta, Katsuyuki ; Tamaoki, Akihiko ; Tokuda, Yoshiyuki ; Nagata, Takuya ; Watanabe, Kazuhiko ; Gemba, Kenichi ; Moritaka, Tomonori ; Horita, Naokatsu ; Takeda, Hiromasa ; Okimoto, Niro ; Takemoto, Mitsuhiro ; Matsuo, Keitaro ; Shinkai, Tetsu ; Tabata, Masahiro ; Ueoka, Hiroshi ; Kanazawa, Susumu ; Tanimoto, Mitsune. / Benefits and adverse events among elderly patients receiving concurrent chemoradiotherapy for locally advanced non-small cell lung cancer : Analysis of the Okayama lung cancer study group trial 0007. In: Journal of Thoracic Oncology. 2011 ; Vol. 6, No. 6. pp. 1087-1091.
@article{75630df3961a41bf9782a0160137c163,
title = "Benefits and adverse events among elderly patients receiving concurrent chemoradiotherapy for locally advanced non-small cell lung cancer: Analysis of the Okayama lung cancer study group trial 0007",
abstract = "Introduction: Thoracic radiotherapy (RT) with concurrent chemotherapy may be offered to selected elderly patients with locally advanced non-small cell lung cancer. The Okayama Lung Cancer Study Group (OLCSG) 0007 trial with patients up to 75 years showed that with concurrent RT, docetaxel and cisplatin (DP) chemotherapy was an alternative to mitomycin C, vindesine, and cisplatin (MVP) chemotherapy. Methods: Of the 99 patients in the DP arm, 73 were younger than 70 years and 26 were 70 years or older. Of the 101 patients in the MVP arm, 75 were younger than 70 years and 26 were 70 years or older. Overall survival (OS) and progression-free survival (PFS) were calculated using the Kaplan-Meier method and were compared using an early period weighted log-rank test. Toxicities and treatment intensities were compared by χ and t tests, respectively. Results: OS and PFS tended to be longer in the DP arm versus MVP arm: median OS (months), 27.5 versus 22.9 (p = 0.109) and 25.6 versus 23.4 (p = 0.064) in the ≥70-year and",
keywords = "Chemotherapy, Elderly, Non-small cell lung cancer, Radiation",
author = "Nagio Takigawa and Katsuyuki Kiura and Yoshihiko Segawa and Katsuyuki Hotta and Akihiko Tamaoki and Yoshiyuki Tokuda and Takuya Nagata and Kazuhiko Watanabe and Kenichi Gemba and Tomonori Moritaka and Naokatsu Horita and Hiromasa Takeda and Niro Okimoto and Mitsuhiro Takemoto and Keitaro Matsuo and Tetsu Shinkai and Masahiro Tabata and Hiroshi Ueoka and Susumu Kanazawa and Mitsune Tanimoto",
year = "2011",
month = "6",
doi = "10.1097/JTO.0b013e318213f86a",
language = "English",
volume = "6",
pages = "1087--1091",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "6",

}

TY - JOUR

T1 - Benefits and adverse events among elderly patients receiving concurrent chemoradiotherapy for locally advanced non-small cell lung cancer

T2 - Analysis of the Okayama lung cancer study group trial 0007

AU - Takigawa, Nagio

AU - Kiura, Katsuyuki

AU - Segawa, Yoshihiko

AU - Hotta, Katsuyuki

AU - Tamaoki, Akihiko

AU - Tokuda, Yoshiyuki

AU - Nagata, Takuya

AU - Watanabe, Kazuhiko

AU - Gemba, Kenichi

AU - Moritaka, Tomonori

AU - Horita, Naokatsu

AU - Takeda, Hiromasa

AU - Okimoto, Niro

AU - Takemoto, Mitsuhiro

AU - Matsuo, Keitaro

AU - Shinkai, Tetsu

AU - Tabata, Masahiro

AU - Ueoka, Hiroshi

AU - Kanazawa, Susumu

AU - Tanimoto, Mitsune

PY - 2011/6

Y1 - 2011/6

N2 - Introduction: Thoracic radiotherapy (RT) with concurrent chemotherapy may be offered to selected elderly patients with locally advanced non-small cell lung cancer. The Okayama Lung Cancer Study Group (OLCSG) 0007 trial with patients up to 75 years showed that with concurrent RT, docetaxel and cisplatin (DP) chemotherapy was an alternative to mitomycin C, vindesine, and cisplatin (MVP) chemotherapy. Methods: Of the 99 patients in the DP arm, 73 were younger than 70 years and 26 were 70 years or older. Of the 101 patients in the MVP arm, 75 were younger than 70 years and 26 were 70 years or older. Overall survival (OS) and progression-free survival (PFS) were calculated using the Kaplan-Meier method and were compared using an early period weighted log-rank test. Toxicities and treatment intensities were compared by χ and t tests, respectively. Results: OS and PFS tended to be longer in the DP arm versus MVP arm: median OS (months), 27.5 versus 22.9 (p = 0.109) and 25.6 versus 23.4 (p = 0.064) in the ≥70-year and

AB - Introduction: Thoracic radiotherapy (RT) with concurrent chemotherapy may be offered to selected elderly patients with locally advanced non-small cell lung cancer. The Okayama Lung Cancer Study Group (OLCSG) 0007 trial with patients up to 75 years showed that with concurrent RT, docetaxel and cisplatin (DP) chemotherapy was an alternative to mitomycin C, vindesine, and cisplatin (MVP) chemotherapy. Methods: Of the 99 patients in the DP arm, 73 were younger than 70 years and 26 were 70 years or older. Of the 101 patients in the MVP arm, 75 were younger than 70 years and 26 were 70 years or older. Overall survival (OS) and progression-free survival (PFS) were calculated using the Kaplan-Meier method and were compared using an early period weighted log-rank test. Toxicities and treatment intensities were compared by χ and t tests, respectively. Results: OS and PFS tended to be longer in the DP arm versus MVP arm: median OS (months), 27.5 versus 22.9 (p = 0.109) and 25.6 versus 23.4 (p = 0.064) in the ≥70-year and

KW - Chemotherapy

KW - Elderly

KW - Non-small cell lung cancer

KW - Radiation

UR - http://www.scopus.com/inward/record.url?scp=79958095948&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958095948&partnerID=8YFLogxK

U2 - 10.1097/JTO.0b013e318213f86a

DO - 10.1097/JTO.0b013e318213f86a

M3 - Article

C2 - 21415777

AN - SCOPUS:79958095948

VL - 6

SP - 1087

EP - 1091

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 6

ER -